Journal of Medicinal Chemistry: Orally Bioavailable Cyclin A/B RxL Inhibitors: optimization of a novel class of macrocyclic peptides to target E2F high and G1–S-checkpoint compromised cancers

Journal of Medicinal Chemistry_Orally Bioavailable Macrocyclic Peptide Cyclin A_B RxL Inhibitors to Treat Cancers with High E2F Activity_J. Shapiro